Developing antibodies that target specific cancer mutations
Official title: A platform for T-cell receptor mimic antibody generation modeled using pHLA-A*11:01 KRAS G12D
Funded at Precision Biotools INC · NIH-11262568 · Data updated 2026-11-12
This study is working on new antibodies that can specifically target a common mutation in cancer called KRASG12D, with the goal of making cancer treatments more effective and with fewer side effects for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Precision Biotools INC NIH-funded |
| Lab location | 1 site (Branford, United States) |
| Project start | July 1, 2023 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $1,221,746 |
| NIH project number | 7R44GM149009-03 |
| Project ID | NIH-11262568 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers harboring KRASG12D mutations who are seeking advanced treatment options.
✕Less likely to help
Patients without KRAS mutations or those with cancers not associated with this specific mutation may not benefit from this research.
What this research studies
This research focuses on creating T cell receptor mimic antibodies that specifically target KRAS mutations, particularly the KRASG12D mutation associated with certain cancers. Using innovative technology, the project aims to enhance the effectiveness of immunotherapies by developing antibodies that can differentiate between mutated and normal proteins. This approach could lead to more precise cancer treatments with fewer side effects for patients. The research is designed to validate these antibodies and assess their potential in improving cancer therapy outcomes.
Why it matters
Potential benefit: If successful, this research could provide patients with more effective and targeted cancer treatments that minimize side effects.
How similar studies have gone: Other research has shown promise in developing targeted therapies for cancer, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
-
Precision Biotools INC
Branford, United States Active
Researchers
- Principal investigator: Weiner, Michael — Precision Biotools INC
- Study coordinator: Weiner, Michael
Related research
Other NIH-funded projects on the same topics.
-
T-cell receptor mimic antibodies to target KRAS G12D in HLA-A*11:01 patients
A new therapy approach uses specialized antibodies to specifically recognize a KRAS G12D cancer mutation in people with the HLA-A*11:01 molecule.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.